Excipients and their role in approved injectable products: Current usage and future directions

PDA Journal of Pharmaceutical Science and Technology

Volumn 65, Issue 3, 2011, Pages 287-332

  Nema, Sandeep ^a   Brendel, Ronald J ^b  

^a PFIZER INC   (United States)

^b MEDTRONIC INC   (United States)

Author keywords

Antioxidant; Buffer; Chelating agent; Excipients; Inactive ingredients; Injectable; Parenteral; Surfactant

Indexed keywords

ANTIINFECTIVE AGENT; ANTIOXIDANT; APTAMER; ARACHIS OIL; BENZYL ALCOHOL; BENZYL BENZOATE; BUFFER; BULKING AGENT; CASTOR OIL; CHELATING AGENT; COTTON SEED OIL; DRUG ADDITIVE; DRUG SOLVENT; EXCIPIENT; GLYCEROL; HEAVY METAL; HYBRID PROTEIN; MACROGOL; MACROGOL 400; MONOCLONAL ANTIBODY; N,N DIMETHYLACETAMIDE; OIL; POLYMER; POLYSORBATE 80; PRESERVATIVE; PROTECTIVE AGENT; SCAFFOLD PROTEIN; STERILE WATER; SURFACTANT; UNINDEXED DRUG; DRUG DOSAGE FORM;

ANTISENSE VECTOR; BOOK; CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); CONCENTRATION (PARAMETERS); DRUG CONTAMINATION; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG MARKETING; EUROPE; FERMENTATION; HUMAN; JAPAN; MEDICAL LITERATURE; PATIENT SAFETY; PRACTICE GUIDELINE; REVIEW; UNITED STATES; INJECTION;

DOSAGE FORMS; EXCIPIENTS; HUMANS; INJECTIONS;

EID: 83755178105     PISSN: 10797440     EISSN: None     Source Type: Journal    
DOI: 10.5731/pdajpst.2011.00634     Document Type: Review

References (109)

1. Robertson, M. I. Regulatory issues with excipients. Int. J. Pharm. 1999, 187, 273-276.
2. Amidon, G. E., Peck, G. E., Block, L. H., Moreton, R. C., Katdare, A., Lafaver, R. and Sheehan, C. 1059 Excipient performance, a proposed new USP General Information Chapter. Pharmacopoeial Forum 2007, 33 (6), 1311-1321.
3. Moreton, C. Functionality and performance of excipients in a quality-by-design world: Part 1. Am. Pharm. Rev. 2009, 12 (1), 40-44.
4. Industry is developing a more profound understanding of excipients. Gold Sheet 2009, September.
5. BP. Parenteral Preparations. In British Pharmacopoeia, Stationary Office: London, 1999; Vol. II, p 1575.
6. EP. Parenteral Preparations. In European Pharmacopoeia, 6 ed.; Council of Europe: Strasbourg, 2009; p 1765.
7. Uchiyama, M. Regulatory status of excipients in Japan. Drug Information Journal 1999, 33 (1), 27-32. (Pubitemid 29104647)
8. nd ed.; Avis, K. E.; Lieberman, H. A.; Lachman, L., Eds.; Marcel Dekker, Inc.: New York, 1992; Vol. 1, pp 173-248.
9. Matthews, B. Excipients used in products approved through the E.U. centralised procedure. The Regulatory Affairs J. 2002, 13 (12), 1036-1044.
10. Matthews, B. Excipients for non-oral routes of administration. The Regulatory Affairs J. 2002, 13 (11), 897-908.
11. Nema, S.; Washkuhn, R. J.; Brendel, R. J. Excipients and their use in injectable products. PDA J. Pharm. Sci. Technol. 1997, 51 (4), 166-171. (Pubitemid 28123757)
12. Powell, M. F.; Nguyen, T.; Baloian, L. Compendium of excipients for parenteral formulations. PDA J. Pharm. Sci. Technol. 1998, 52 (5), 236-311.
13. Strickley, R. G. Parenteral formulations of small molecules therapeutics marketed in the United States (1999). Part I. PDA J. Pharm. Sci. Technol. 1999, 53 (6), 324-349. (Pubitemid 30100071)
14. Strickley, R. G. Parenteral formulations of small molecules therapeutics marketed in the United States (1999). Part II. PDA J. Pharm. Sci. Technol. 2000, 54 (1), 69-96. (Pubitemid 30183804)
15. Strickley, R. G. Parenteral formulations of small molecules therapeutics marketed in the United States (1999). Part III. PDA J. Pharm. Sci. Technol. 2000, 54 (2), 152-169. (Pubitemid 30321145)
16. Wang, Y. J.; Hanson, M. A. Parenteral formulations of proteins and peptides: stability and stabilizers. PDA Pharm. J. Sci. Technol. 1988, 42 supplement, S4-S26.
17. Wang, Y. J.; Kowal, R. R. Review of excipients and pH's for parenteral products used in the United States. J. Parenter. Sci. Technol. 1980, 34 (6), 452.
18. GenRx. Mosby's GenRx, 8 ed.; Mosby-Year Book, Inc.: St. Louis, 1998.
19. Physician's Desk Reference, 63 ed.; Thomson Corporation: Toronto, 2009.
20. FDA. Inactive Ingredient Guide. In Division of Drug Information Resources; FDA, CDER: 2009.
21. Rowe, R. C.; Sheskey, P. J.; Quinn, M. E. Handbook of Pharmaceutical Excipients, 6 ed.; The Pharmaceutical Press: London, 2009.
22. Trissel, L. A. Handbook on Injectable Drugs, 10 ed.; American Society of Health-System Pharmacists, Inc: Bethesda, MD, 1998.
23. EMEA. Note for Guidance on Quality of Water for Pharmaceutical Use. In CPMP/QWP/158/01 revision-EMEA/CVMP/115/01 revision: May 2002.
24. EMEA. Reflection Paper on Water for Injection Prepared by Reverse Osmosis. In EMEA/CHMP/ CVMP/QWP/28271/2008: 5 March 2008.
25. Sweetana, S.; Akers, M. J. Solubility principles and practices for parenteral drug dosage form development. PDA J. Pharm. Sci. Technol. 1996, 50 (5), 330-342. (Pubitemid 26392756)
26. Yalkowsky, S. H.; Roseman, T. J. Solubilization of Drugs by Cosolvents. In Techniques of Solubilization of Drugs; Marcel Dekker, Inc.: New York, 1981; pp 91-134.
27. Hancock, B. C.; York, P.; Rowe, R. C. The use of solubility parameters in pharmaceutical dosage form design. Int. J. Pharm. 1997, 148, 1-21. (Pubitemid 27152212)
28. Rubino, J. T.; Yalkowsky, S. H. Cosolvency and cosolvent polarity. Pharm. Res. 1987, 4 (3), 220-230. (Pubitemid 17110396)
29. Brazeau, G. A.; Cooper, B.; Svetic, K. A.; Smith, C. L.; Gupta, P. Current perspectives on pain upon injection of drugs. J. Pharm. Sci. 1998, 87 (6), 667-677. (Pubitemid 28268564)
30. Brazeau, G. A.; Fung, H. Use of an in vivo model for the assessment of muscle damage from intramuscular injections: in vitro-in vivo correlation and predictability with mixed solvent systems. Pharm. Res. 1989, 6 (9), 766-771. (Pubitemid 19247846)
31. Reed, K. W.; Yalkowsky, S. Lysis of human red blood cells in the presence of various cosolvents. J. Parenter. Sci. Technol. 1985, 39 (2), 64-69.
32. Yalkowsky, S. H.; Krzyzaniak, J. F.; Ward, G. H. Formulation-related problems associated with intravenous drug delivery. J. Pharm. Sci. 1998, 87 (7) 787-796. (Pubitemid 28319406)
33. Mottu, F.; Laurent, A.; Rufenacht, D. A.; Doelker, E. Organic solvents for pharmaceutical parenterals and embolic liquids: a review of toxicity data. PDA J. Pharm. Sci. Technol. 2000, 54 (6), 456-465.
34. USP. 1 Injections. In USP, 32 ed.; U.S. Pharmacopeial Convention, Inc.: Rockville, MD, 2009.
35. JP. Injections. In The Japanese Pharmacopoeia, XV ed.; 2006, p 10.
36. Johnson, D. M.; Gu, L. C. Autoxidation and Antioxidants. In Encyclopedia of Pharmaceutical Technology; Swarbrick, J.; Boylan, J. C., Eds. Marcel Dekker, Inc.: New York, 1988; Vol. 1, pp 415-449.
37. Herman, A. C.; Boone, T. C.; Lu, H. S. Characterization, Formulation, and Stability of Neupogen (Filgrastim), a Recombinant Human Granulocyte-Colony Stimulating Factor. In Formulation, Characterization, and Stability of Protein Drugs: Case Histories; Pearlman, R.; Wang, Y. J., Eds.; Plenum Press: New York, 1996; Vol. 9, p 325.
38. Fatouros, A.; Osterberg, T.; Mikaelsson, M. Recombinant factor VIII SQ-influence of oxygen, metal ions, pH and ionic strength on its stability in aqueous solution. Int. J. Pharm. 1997, 155 (1), 121-131. (Pubitemid 27368129)
39. Stadtman, E. R. Metal ion-catalyzed oxidation of proteins: biochemical mechanism and biological consequences. Free Radical Biol. Med. 1990, 9 (4), 315-325. (Pubitemid 120036900)
40. Enever, R. P.; Po, A. L. W.; Shotton, E. Factors influencing decomposition rate of amitriptyline hydrochloride in aqueous solution. J. Pharm. Sci. 1977, 66 (8), 1087-1089. (Pubitemid 8167327)
41. Munson, J. W.; Hussain, A.; Bilous, R. Precautionary note for use of bisulfite in pharmaceuti- cal formulations. J. Pharm. Sci. 1977, 66 (12), 1775-1776. (Pubitemid 8246701)
42. Akers, M. J. Antioxidants in pharmaceutical products. J. Parenter. Sci. Technol. 1982, 36 (5), 222-228.
43. Committee for Proprietary Medicinal Products (CPMP). Note for Guidance on inclusion of Antioxidants and Antimicrobial Preservatives in Medicinal Products. In CPMP: January 1998.
44. EMEA. Guideline on Excipients in the Dossier for Application for Marketing Authorization of a Medical Product. In EMEA/CHMP/QWP/396951/2006: 19 June 2007.
45. Dabbah, R. The use of preservatives in compendial articles. Pharmacopeial Forum 1996, 22 (4), 2696.
46. Martindale: The Extra Pharmacopoeia. 31 ed.; Royal Pharmaceutical Society: London, 1996; p 1128.
47. British Pharmaceutical Codex; Royal Pharmaceutical Society: London, 1973; p 100.
48. Oishi, S. Effects of propyl paraben on the male reproductive system. Food Chem. Toxicol. 2002, 40 (12), 1807-1813. (Pubitemid 35284152)
49. Oishi, S. Effects of butylparaben on the male reproductive system in mice. Arch. Toxicol. 2002, 76 (7), 423-429. (Pubitemid 34762265)
50. Oishi, S. Lack of spermatotoxic effects of methyl and ethyl esters of p-hydroxybenzoic acid in rats. Food Chem. Toxicol. 2004, 42, 1845-1849. (Pubitemid 39200463)
51. Hoberman, A. M. Schreur, D. K.; Leazar, T.; Daston, D. P.; Carthew, P.; Re, T.; Loretz, L.; Mann, P. Lack of effect of butylparaben and methylparabben on the reproductive system in male rats. Birth Defects Res. B Dev. Reprod. Toxicol. 2008, 83 (2), 123-133. (Pubitemid 351631347)
52. Dabbah, R. Harmonization of microbiological methods-a status report. Pharmacopeial Forum 1997, 23 (6), 5334-5344.
53. European Pharmacopoeia, 3 ed.; Council of Europe: Strasbourg, 1997; p 286.
54. USP. 51 Antimicrobial Effectiveness Testing. In USP, 32 ed.; U.S. Pharmacopeial Convention, Inc.: Rockville, MD, 2009.
55. CPMP. Note for Guidance on Maximum Shelflife for Sterile Products for Human Use After First Opening or Following Reconstitution. CPMP, July 1998.
56. Lam, X. M.; Costantino, H. R.; Overcashier, D. E.; Nguyen, T. H.; Hsu, C. C. Replacing succinate with glycolate buffer improves the stability of lyophilized interferon-gamma. Int. J. Pharm. 1996, 142 (1), 85-95. (Pubitemid 26343833)
57. Piedmonte, D. M.; Summers, C.; McAuley, A.; Karamujic, L.; Ratnaswamy, G. Sorbitol crystallization can lead to protein aggregation in frozen protein formulations. Pharm. Res. 2007, 24 (1), 136-146. (Pubitemid 44902578)
58. Pikal, M. J. The Correlation of Structural Relaxation Time with Pharmaceutical Stability. Freeze-Drying of Pharmaceuticals and Biologicals Conference, Brownsville, VT, September 23-26, 1998.
59. Arakawa, T.; Kita, Y.; Carpenter, J. F. Proteinsolvent interactions in pharmaceutical formulations. Pharm. Res. 1991, 8 (3), 285-291.
60. Miller, D. P.; Anderson, R. E.; de Pablo, J. J. Stabilization of lactate dehydrogenase following freeze-thawing and vacuum-drying in the presence of trehalose and borate. Pharm. Res. 1998, 15 (8), 1215-1221.
61. Carpenter, J. F.; Crowe, J. H. Modes of stabilization of a protein by organic solutes during desiccation. Cryobiology 1998, 25 (5), 459-470.
62. Baumann, T. J.; Smythe, M. A.; Kaufmann, K.; Miloboszewski, Z.; O'Malley, J.; Fudge, R. P. Dissolution times of adriamycin and adriamycin RDF. Am. J. Hosp. Pharm. 1988, 45, 1667.
63. Jain, N. K.; Jain, S.; Singhai, A. K. Enhanced solubilization and formulation of an aqueous in- jection of piroxicam. Pharmazie 1997, 52 (12), 942-946. (Pubitemid 28010882)
64. Meyer, J. D.; Manning, M. C. Hydrophobic ion pairing: altering the solubility properties of biomolecules. Pharm. Res. 1998, 15 (2), 188-192.
65. Wang, Y. J.; Dahl, T. C.; Leesman, G. D.; Monkhouse, D. C. Optimization of autoclave cycles and selection of formulation for parenteral product. Part II: Effect of counter-ion on pH and stability of diatrizoic acid at autoclave temperatures. J. Parenter. Sci. Technol. 1984, 38 (2), 72-77. (Pubitemid 14125736)
66. JPE. Japanese Pharmaceutical Excipients Directory. Yakuji Nippo, Ltd: Tokyo, 2004.
67. Excipients in Pharmaceutical Dosage Forms: The Challenge of the 21st Century. Nice, France, May 14-15, 1998.
68. PF. Benzyl alcohol. Pharmacopeial Forum 1995, 21 (5).
69. nd ed.; U.S. Pharmacopeial Convention, Inc.: Rockville, MD, 2009.
70. Excipients in the Label and Package Leaflet of Medicinal Products for Human Use. In European Commission; July 2003; Guidelines Medicinal products for human use Safety, environment and information Vol. 3B.
71. CPMP. Note for Guidance on the Use of Bovine Serum in the Manufacture of Human Biological Medicinal Products. In CPMP/BWP/1793/02:18 June 2003.
72. CPMP. Note for Guidance on Development Pharmaceutics. In CPMP: July 1998.
73. Akers, M. J. Excipient-drug interactions in parenteral formulations. J. Pharm. Sci. 2002, 91 (11), 2283-2300. (Pubitemid 35231192)
74. Paul, W. L. Excipient intake and heavy metals limits. Pharmacopeial Forum 1995, 21 (6), 1638-1640.
75. Aluminum in large and small volume parenterals used in total parenteral nutrition. Federal Register 1998, 63 (2), 176-185.
76. FDA. Guideline on Validation of the Limulus Amebocyte Lysate Test as an End-Product Test for Human and Animal Parenteral Drugs. In Biological Products and Medical Devices, FDA: December 1987.
77. Opalchenova, G. A. Comparison of the microbial limit tests in the British, European, and United States Pharmacopeias and recommendation for harmonization. Pharmacopeial Forum 1994, 20 (4), 7872-7877.
78. Taylor, P. Regulation for excipients is brewing across the Atlantic. Pharm. Technol. 2009, 33 (2), 86-87.
79. Fatalities Associated with Ingestion of Diethylene Glycol-Contaminated Glycerin Used to Manufacture Acetaminophen Syrup-Haiti, November 1995-June 1996, In Morbidity and Mortality Weekly Report, U.S. Department of Health and Human Services: August 2, 1996; Vol. 45, pp 649-650.
80. FDA. Pharmaceutical Components at Risk for Melamine Contamination. U.S. Department of Health and Human Services, FDA.; August 2009.
81. FDA. Interim Inactive Ingredient Policy. Office of Generic Drugs (OGD), FDA, 1994.
82. Weiner, M.; Bernstein, I. L. Adverse Reactions to Drug Formulation Agents: A Handbook of Excipients; Marcel Dekker, Inc: New York, NY, 1989.
83. USP. 1074 Excipient Biological Safety Evaluation Guidelines. In USP, 32 ed.; U.S. Pharmacopeial Convention, Inc: Rockville, MD, 2009.
84. FDA. Nonclinical Studies for the Safety Evaluation of Pharmaceutical Excipients. Guidance for Industry; FDA; May 2005.
85. Matthews, B., BSE/TSE risks associated with active pharmaceutical ingredients and starting materials: the situation in Europe and the global implications for healthcare manufacturers. PDA J. Pharm. Sci. Technol. 2001, 55 (5), 295-328.
86. CPMP. Note for Guidance on Minimizing the Risk of Transmitting Animal Spongiform Encephalopathy Agents via Medicinal Products. In CPMP: 21 April 1999.
87. FDA. The Sourcing and Processing of Gelatin to Reduce the Potential Risk Posed by Bovine Spongiform Encephalopathy (BSE) in FDARegulated Products for Human Use. Guidance for Industry. U.S. Department of Health and Human Services, FDA: September 1997.
88. EMEA. Gelatin for Use in Pharmaceuticals: Explanatory Note. In EMEA/CPMP/4306/00/v0.2:13 December 2000.
89. EMEA. First Cases of BSE in USA and Canada: Risk Assessment of Ruminate Materials Originating from USA and Canada. In EMEA/CHMP/ BWP/27/04:21 July 2004.
90. EMEA. CHMP Position Statement on Creutzfeldt-Jakob Disease and Plasma-Derived and Urine Derived Medicinal Products. In EMEA/CPMP/BWP/ 2879/02/rev 1:23 June 2004.
91. Chuang, V. T. G.; Kragh-Hansen, U.; Otagiri, M. Pharmaceutical strategies utilizing recombinant human serum albumin. Pharm. Res. 2002, 19 (5).
92. CPMP. Position State on Polysorbate 80. In CPMP/BWP/1952/98:22 October 1998.
93. Frank, D. W.; Gray, J. E.; Weaver, R. N. Cyclodextrin nephrosis in the rat. Am. J. Pathol. 1976, 83 (2) 367-382.
94. Stella, V. J.; Rajewski, R. A. Cyclodextrins: their future in drug formulation and delivery. Pharm. Res. 1997, 14 (5), 556-567. (Pubitemid 27220271)
95. Thompson, D. O. Cyclodextrins- enabling excipients: their present and future use in pharmaceuticals. Crit. Rev. Ther. Drug Carrier Sys. 1997, 14 (1), 1-104. (Pubitemid 27079973)
96. Loftsson, T.; Johannesson, H. R. The influence of cyclodextrins on the stability of cephalothin and aztreonam in aqueous solutions. Die Pharmazie 1994, 49, 292-293. (Pubitemid 24119942)
97. Lehner, S. J.; Muller, B. W.; Seydel, J. K. Effect of hydroxylpropyl-beta-cyclodextrin on the antimicrobial action of preservatives. J. Pharm. Pharmacol. 1994, 46, 186-191. (Pubitemid 24081954)
98. Felt, O.; Buri, P.; Gurny, R. Chitosan: A unique polysaccharide for drug delivery. Drug Dev. Ind. Pharm. 1998, 24 (11), 979-993. (Pubitemid 28460237)
99. Jain, R.; Shah, N. H.; Malick, A. W.; Rhodes, C. T. Controlled drug delivery by biodegradable poly(ester) devices: different preparative approaches. Drug Dev. Ind. Pharm. 1998, 24 (8), 703-727. (Pubitemid 28346446)
100. Middleton, J. C.; Tipton, A. J. Synthetic biodegradable polymers as medical devices. Medical Plastics Biomaterials 1998, 5 (2) 30-39.
101. Pettit, D. K.; Lawter, J. R.; Huang, W. J.; Pankey, S. C.; Nightlinger, N. S.; Lynch, D. H.; Schuh, J. A. C. L.; Morrissey, P. J.; Gombotz, W. R. Characterization of poly(glycolide-co- D,L-lactide)/poly(D,L-lactide) microspheres for controlled release of GM-CSF. Pharm. Res. 1997, 14 (10), 1422-1430. (Pubitemid 27481074)
102. Katre, N. V.; Asherman, J.; Schaefer, H. Multivesicular liposome (DepoFoam™) technology for the sustained delivery of Insulin-like Growth Factor-I. J. Pharm. Sci. 1998, 87 (11), 1341-1346. (Pubitemid 28514138)
103. Wang, P.; Johnston, T. P. Sustained-release Interleukin- 2 following intramuscular injection in Rats. Int. J. Pharm. 1995, 113 (1), 73-81. (Pubitemid 24323036)
104. Moghimi, S. M. mechanisms regulating body distribution of nanospheres conditioned with pluronic and tetronic block co-polymers. Adv. Drug Deliv. Rev. 1995, 16 (2-3), 183-193.
105. Zheng, J. Y.; Bosch, H. W. Sterile filtration of NanoCrystal™ drug formulations. Drug Dev. Ind. Pharm. 1997, 23 (11), 1087-1093. (Pubitemid 27454098)
106. Knepp, V. M.; Muchnik, A.; Oldmark, S.; Kalashnikova, L. Stability of non-aqueous suspension formulations of plasma-derived factor IX and recombinant human alpha interferon at elevated temperatures. Pharm. Res. 1998, 15 (7), 1090-1095. (Pubitemid 28356928)
107. Sullivan, S. A.; Gilley, R. M.; Gibson, J. W.; Tipton, A. J. Delivery of taxol and other antineoplastic agents from a novel system based on sucrose acetate isobutyrate. Pharm. Res. 1997, 14 (11), 291.
108. Gombotz, W. R.; Pettit, D. K. Biodegradable polymers for proteins and peptide drug delivery. Bioconjug. Chem. 1995, 6 (4), 332-351.
109. Apte, S. R.; Ogwu, S. O. A review and classification of emerging excipients in parenteral medications. Pharm. Technol. 2003, 27 (3), 46-60.